Ajinomoto Co., Inc. to Acquire Forge Biologics for $620M

Ajinomoto Co., Inc. (“Ajinomoto Co.”; TYO: 2802) and Forge Biologics (Forge), announce that they have entered into a definitive agreement by which Ajinomoto Co., will acquire Forge, a leading manufacturer of genetic medicines, in an all-cash deal for $620 million. Forge is a viral vector and plasmid contract development and manufacturing organization (CDMO) and clinical-stage therapeutics company, enabling access to potentially life-changing gene therapies by bringing them from concept to reality. All development and manufacturing is done at the Hearth, Forge‚Äôs 200,000 square foot custom-designed cGMP facility in Columbus, Ohio, where the business has over 300 employees.

Read the full article: Ajinomoto Co., Inc. to Acquire Forge Biologics for $620M //

Source: https://www.businesswire.com/news/home/20231112506083/en/Ajinomoto-Co.-Inc.-to-Acquire-Forge-Biologics-for-620-Million1

Leave a Comment

Your email address will not be published.

Scroll to Top